ABSTRACT
Throughout Europe, the AIDS epidemic has brought about major changes in public policy on drug abuse. While harm reduction policies were firmly established in the UK and the Netherlands by the early 1980s (Berridge, 1994), such was not the case in countries such as France. Here, the response differed both from the UK and The Netherlands and from the zero-tolerance option in the USA where, for example, needle provision remains unsubsidised by public funds (Des Jarlais, 1995).
